Docetaxel

Org: Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Southern Medical University, The First People’s Hospital of Foshan,

Abstract

Safety, tolerability, and quality of life (QoL) of single-agent plinabulin (Plin) for the prevention of docetaxel (Doc) chemotherapy (chemo)-induced neutropenia (CIN) in non-small cell lung cancer (NSCLC) patients (pts) from two randomized trials.

Org: Stanford Cancer Institute, BeyondSpring Pharmaceuticals, Inc.,

Abstract

Prognostic value of baseline immune suppressive biomarkers to select non-small cell lung cancer (NSCLC) patients (pts) likely to benefit from the plinabulin/docetaxel (Plin/Doc) combination.

Org: Piedmont Cancer Institue, BeyondSpring Pharmaceuticals, Inc.,

Abstract

Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience.

Org: University of Texas MD Anderson Cancer Center, The University of Texas at MD Anderson Cancer Center, MD Anderson Cancer Center, Department of Leukemia,

Abstract

Characterization of drug and non-drug interactions in patients treated in medical oncology.

Org: Faculty of Medicine, University of Tlemcen, Department of Medicine, Laboratoire Toxicomed, University of Tlemcen, Department of Medical Oncology, CHU Tlemcen,

Abstract

Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial.

Org: Department of Respiratory Diseases, ELK Berlin, Universitätsklinikum Gießen und Marburg, Medizinische Klinik IV, Organonkologie, Innere Medizin V, Medizinische Klinik, Universitätskliniken des Saarlandes, Department of Internal Medicine, Klinikum Chemnitz GmbH,

Abstract

Prevention of chemotherapy-induced neutropenia (CIN) with plinabulin (Plin) vs placebo (Plac) in patients (pts) with non-small cell lung cancer (NSCLC) treated with docetaxel (Doc): A pooled analysis from 3 randomized trials.

Org: Stanford Cancer Institute, Stanford, CA, BeyondSpring Pharmaceuticals, Inc., New York, NY, Newyork, NY,

Abstract

Real-world efficacy of chemotherapy in patients with advanced extramammary Paget's disease: A retrospective, multicenter study of 204 Japanese patients.

Org: Kumamoto University Hospital, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Nagoya City University Graduate School of Medical Sciences, National Cancer Center Hospital East, Kashiwa, Japan, Graduate School of Medicine, Chiba University,

Product

Docetaxel + Cisplatin HIPEC

Product

Methotrexate

Product

ADT with or without docetaxel plus abiraterone acetate, prednisone, and prostate radiotherapy

Product

IMM2520

Product

Gemcitabine, Doxorubicin, Docetaxel, Nivolumab

Product

doxorubicin, vinblastine, cyclophosphamide, methotrexate, 5-fluorouracil